May 11, 2026 – Thermo Fisher Scientific Inc. earned a Leader designation among contract research organizations (CROs) in the 2026 ISG Provider Lens Life Sciences Digital Services report, underscoring the company’s continued investment in digital innovation across the clinical development continuum.
The recognition highlights the strength of Thermo Fisher’s PPD™ clinical research business, which is recognized for its capabilities in clinical development, patient engagement, and digital evolution in pharmacovigilance and regulatory affairs. The independent study, conducted by Information Services Group (ISG), evaluates leading providers based on technology innovation, portfolio strength and competitive positioning.
ISG cited Thermo Fisher’s end-to-end approach to clinical development, including its ability to integrate decentralized and hybrid trial models with advanced data and analytics. By embedding digital technologies and AI-driven insights throughout the clinical trial lifecycle, the company helps customers reduce operational complexity and improve the predictability of global development programs.
The company was also recognized for its progress in pharmacovigilance and regulatory affairs, where it continues to advance the use of artificial intelligence and machine learning to support safety case processing, signal detection and regulatory intelligence. These capabilities enable more proactive risk management and support compliance across global markets…